1 citations
,
May 2019 in “The Journal of Sexual Medicine” This case report describes two women experiencing hormonally associated vestibulodynia and female arousal disorder, potentially linked to the use of spironolactone for androgen-mediated cutaneous disorders.
54 citations
,
May 2018 in “International journal of risk & safety in medicine” This study observed enduring sexual dysfunction reported in 300 cases globally following the use of SSRIs, finasteride, and isotretinoin, with common symptoms like genital anaesthesia and loss of libido.
11 citations
,
July 2019 in “The Journal of Sexual Medicine” This study suggests that spironolactone may cause hormonally associated vestibulodynia and female sexual arousal disorder, with symptoms improving after discontinuation and use of a topical estrogen/testosterone gel.
14 citations
,
January 2001 in “Primary Care Update for Ob/gyns” This review discusses the challenges in addressing female sexual dysfunction, focusing on the complexities of female sexual response, levels of dysfunction, clinical identification, and existing treatments, but presents no new clinical findings.
6 citations
,
June 2000 in “Psychiatric Services” This article discusses the sexual health issues faced by postmenopausal women and highlights the need for more research and tailored treatments, but it reports no new clinical results.
